HC Wainwright Forecasts Strong Price Appreciation for BridgeBio Oncology Therapeutics (NASDAQ:BBOT) Stock

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) had its target price increased by equities researchers at HC Wainwright from $27.00 to $29.00 in a research note issued to investors on Friday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. HC Wainwright’s price objective points to a potential upside of 178.31% from the company’s previous close.

BBOT has been the topic of several other research reports. Stifel Nicolaus initiated coverage on BridgeBio Oncology Therapeutics in a report on Tuesday, February 10th. They issued a “buy” rating and a $23.00 price target on the stock. Weiss Ratings initiated coverage on BridgeBio Oncology Therapeutics in a report on Wednesday, January 14th. They set a “sell (d+)” rating for the company. Finally, Raymond James Financial upgraded shares of BridgeBio Oncology Therapeutics to a “moderate buy” rating in a research report on Friday, January 9th. Three investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $26.00.

BridgeBio Oncology Therapeutics Stock Up 5.4%

BBOT opened at $10.42 on Friday. The firm has a market cap of $833.50 million, a PE ratio of -10.12 and a beta of 0.28. BridgeBio Oncology Therapeutics has a one year low of $8.50 and a one year high of $14.87.

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) last issued its quarterly earnings data on Thursday, March 5th. The company reported ($0.49) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.67) by $0.18.

Hedge Funds Weigh In On BridgeBio Oncology Therapeutics

Institutional investors have recently modified their holdings of the company. CIBC Private Wealth Group LLC bought a new stake in BridgeBio Oncology Therapeutics in the 4th quarter worth approximately $63,000. XTX Topco Ltd grew its position in BridgeBio Oncology Therapeutics by 22.4% during the fourth quarter. XTX Topco Ltd now owns 28,633 shares of the company’s stock valued at $358,000 after acquiring an additional 5,249 shares during the last quarter. Persistent Asset Partners Ltd bought a new position in BridgeBio Oncology Therapeutics during the fourth quarter valued at approximately $107,000. Squarepoint Ops LLC purchased a new position in shares of BridgeBio Oncology Therapeutics during the fourth quarter worth approximately $144,000. Finally, Quadrature Capital Ltd bought a new stake in shares of BridgeBio Oncology Therapeutics in the 4th quarter worth approximately $162,000. 54.89% of the stock is currently owned by institutional investors.

Key BridgeBio Oncology Therapeutics News

Here are the key news stories impacting BridgeBio Oncology Therapeutics this week:

• Positive Sentiment: Publication of peer‑reviewed preclinical data for BBO‑11818 (panKRAS) in Cancer Discovery, highlighting potent activity against KRAS G12D/V/C, ON/OFF state inhibition, strong selectivity, and combination potential — adds scientific validation to BBOT’s lead KRAS program. Read More.
• Positive Sentiment: Early Phase 1 KONQUER‑101 clinical signals for BBO‑11818 (including a reported confirmed partial response in PDAC and encouraging anti‑tumor activity) support near‑term clinical upside and future data readouts expected H2 2026. Read More.
• Positive Sentiment: Quarterly results: BBOT reported EPS of ($0.49) vs. consensus ($0.67), beating estimates — a near‑term financial surprise that can reduce investor uncertainty around cash‑burn guidance and valuation assumptions. Read More.
• Positive Sentiment: HC Wainwright raised its price target to $29 and reiterated a Buy, signaling stronger sell‑side conviction and providing a high upside reference for investors. Read More.
• Neutral Sentiment: Corporate update/Q4 & FY‑2025 filing recap: BBOT summarized clinical progress across three RAS‑pathway programs (BBO‑8520, BBO‑11818, BBO‑10203) and reiterated combination strategies — useful context but largely already reflected in recent releases. Read More.
• Neutral Sentiment: Short‑interest data reported anomalies (0 shares / NaN change) for early March — appears to be a data glitch and unlikely to meaningfully explain price moves.
• Negative Sentiment: Key risk: important clinical and regulatory milestones (additional BBO‑11818 data and combination studies) are scheduled for H2 2026 — the multi‑quarter timeline sustains execution risk and valuation uncertainty until those readouts.

About BridgeBio Oncology Therapeutics

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) is a publicly traded biotechnology company focused on discovering and developing therapies for cancer. The company concentrates on translating scientific insights into clinical-stage programs aimed at addressing oncology indications with unmet medical need.

BridgeBio Oncology’s activities center on research and development of investigational therapeutics, advancing drug candidates through preclinical studies and clinical trials. Its work typically involves in-house discovery efforts and collaborations with academic and industry partners to identify targets, optimize compounds, and generate the clinical data needed to support regulatory development.

Public information about BridgeBio Oncology Therapeutics’ specific programs, geographic operations and leadership is limited in the sources available here.